Conhecimento e percepção de riscos do uso de anticoncepcionais e terapia hormonal: Implicações para a educação em saúde.

Karina Kathleen De Carvalho Silva; Kamila Nicole De Oliveira Rocha; Gustavo Alvarenga Rocha; GUSTAVO

Authors

Karina Kathleen De Carvalho Silva Biomédica formada pela Faculdade de Minas – FAMINAS BH.
Kamila Nicole De Oliveira Rocha Biomédica formada pela Faculdade de Minas – FAMINAS BH.
Gustavo Alvarenga Rocha Médico Ginecologista e Obstetra e Ultrassonografista do Hospital Unimed Betim
GUSTAVO Professor orientador dos cursos de Biomedicina, Farmácia, Medicina da Faculdade de Minas – FAMINAS BH, Belo Horizonte, MG, Brasil. Doutor pelo Programa de Pós-graduação em Ciências Aplicadas à Saúde do Adulto da Faculdade de Medicina da Universidade Federal de Minas Gerais, Brasil. https://orcid.org/0000-0003-4909-3829

Keywords:

Hormonal contraception, Hormone replacement therapy, Women’s health, Risk perception

Abstract

Hormonal contraceptives are widely used by women of reproductive age, offering benefits such as menstrual cycle regulation and reduced risk of endometrial and ovarian cancer, but also carrying potential risks, including venous thromboembolism and breast cancer during current use. Assessing women’s knowledge and risk perception is essential for safe and informed choices. This cross-sectional, observational, quantitative study included 425 participants who completed an electronic questionnaire addressing sociodemographic characteristics, contraceptive methods, gynecological follow-up, and risk perception. Most were 18–29 years old (63%) and had complete or incomplete higher education (81%). The oral contraceptive pill was the most frequently used method (34%), followed by condoms (28%). Annual gynecological follow-up was reported by 42%, while 19% reported no regular consultations. Although 94.8% acknowledged risks related to hormonal use, their knowledge was mostly generic. These findings highlight the need for structured educational strategies and individualized clinical counseling that provide balanced information on risks and benefits, thereby supporting more informed reproductive decisions.

Downloads

Download data is not yet available.

Author Biography

GUSTAVO, Professor orientador dos cursos de Biomedicina, Farmácia, Medicina da Faculdade de Minas – FAMINAS BH, Belo Horizonte, MG, Brasil. Doutor pelo Programa de Pós-graduação em Ciências Aplicadas à Saúde do Adulto da Faculdade de Medicina da Universidade Federal de Minas Gerais, Brasil.

Biomédico, habilitado em Análises Clínicas, Docência e Auditoria. Possui experiência em instituições de ensino e saúde, de diferentes níveis e complexidade, atuando com atividades acadêmico-administrativas, gestão de equipe e foco em resultados e desenvolvimento de competências organizacionais conectado à diretriz estratégica da instituição. A vivência profissional aliada à formação acadêmica foi determinante para o desenvolvimento de competências relacionadas à coordenação de equipes, gestão por processos, pensamento da melhoria contínua e inovação, cultura para a qualidade, Ensino e Docência no Ensino Superior.

References

APPLEBY et al.. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet, 370, n. 9599, p. 1609-1621, Nov 10 2007.

BRANDÃO, J. D. P.; MACHADO, R. B.; CARDOSO, A. C. F. Knowledge, Use, and Perception of Brazilian Women about Contraceptive Methods: An Observational Study. Women's Health Reports, 5, n. 1, p. 460-472, 2024.

COLLABORATIVE GROUP ON HORMONAL FACTORS IN BREAST, C. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet, 394, n. 10204, p. 1159-1168, Sep 28 2019.

CURTIS et al.. Using updated clinical recommendations to support contraceptive decision-making: U.S. medical eligibility criteria for contraceptive use, 2024. Contraception, p. 111015, Jul 14 2025.

EVANGELISTA, J. D. S.; OLIVEIRA, L. S. D. S. V.; DEUNER, M. C. Eficácia e segurança dos anticoncepcionais hormonais orais combinados: revisão de literatura. 7 2024.

HULLEYet al.. Designing Clinical Research. Lippincott Williams & Wilkins, a Wolters Kluwer business, 2013. 978-1-60831-804-9.

NATIONAL CANCER INSTITUTE, N. Oral Contraceptives and Cancer Risk. About Cancer, 2018. Disponível em: https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/oral-contraceptives-fact-sheet.

NORTH AMERICAN MENOPAUSE, S. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29, n. 7, p. 767-794, Jul 1 2022.

OLIVEIRA et al.. Fatores de risco cardiovascular, saberes e práticas de cuidado de mulheres: possibilidade para rever hábitos. Escola Anna Nery, 26, 2022.

PONCE DE LEON et al.. Contraceptive use in Latin America and the Caribbean with a focus on long-acting reversible contraceptives: prevalence and inequalities in 23 countries. Lancet Glob Health, 7, n. 2, p. e227-e235, Feb 2019.

UNITED NATIONS, D. O. E. A. S. A., POPULATION DIVISION. Contraceptive Use by Method 2019: Data Booklet. 2019. 978-92-1-148329-1.

VINOGRADOVA, Y.; COUPLAND, C.; HIPPISLEY-COX, J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ, 350, p. h2135, May 26 2015.

WINNER et al.. Effectiveness of long-acting reversible contraception. N Engl J Med, 366, n. 21, p. 1998-2007, May 24 2012.